Barclays PLC Has $4.45 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Barclays PLC boosted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 37.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 511,522 shares of the biopharmaceutical company's stock after purchasing an additional 138,441 shares during the quarter. Barclays PLC owned 0.33% of Ocular Therapeutix worth $4,451,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in shares of Ocular Therapeutix by 49.6% in the second quarter. Bank of New York Mellon Corp now owns 495,635 shares of the biopharmaceutical company's stock valued at $3,390,000 after purchasing an additional 164,383 shares in the last quarter. Banco Santander S.A. raised its stake in shares of Ocular Therapeutix by 81.3% in the second quarter. Banco Santander S.A. now owns 377,368 shares of the biopharmaceutical company's stock valued at $2,581,000 after acquiring an additional 169,172 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Ocular Therapeutix by 757.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,044 shares of the biopharmaceutical company's stock worth $219,000 after acquiring an additional 28,309 shares during the last quarter. Atlas Capital Advisors LLC acquired a new stake in shares of Ocular Therapeutix in the second quarter valued at $34,000. Finally, Aptus Capital Advisors LLC acquired a new stake in Ocular Therapeutix in the 2nd quarter valued at about $1,798,000. 59.21% of the stock is owned by institutional investors.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 2,948 shares of the firm's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the sale, the insider now owns 269,059 shares of the company's stock, valued at $2,424,221.59. This trade represents a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 3.50% of the company's stock.

Ocular Therapeutix Trading Up 0.6 %

Shares of Ocular Therapeutix stock traded up $0.05 on Friday, hitting $8.50. 1,431,144 shares of the company's stock traded hands, compared to its average volume of 1,767,917. Ocular Therapeutix, Inc. has a one year low of $3.76 and a one year high of $11.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The stock has a market capitalization of $1.34 billion, a PE ratio of -6.44 and a beta of 1.19. The firm's 50-day moving average price is $9.98 and its two-hundred day moving average price is $8.62.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Scotiabank started coverage on shares of Ocular Therapeutix in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.71.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.